Profile data is unavailable for this security.
About the company
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
- Revenue in USD (TTM)5.54bn
- Net income in USD1.44bn
- Incorporated1999
- Employees15.80k
- LocationEdwards Lifesciences CorpOne Edwards WayIRVINE 92614United StatesUSA
- Phone+1 (949) 250-2500
- Fax+1 (302) 655-5049
- Websitehttps://www.edwards.com
Mergers & acquisitions
| Acquired company | EW:NYQ since announced | Transaction value |
|---|---|---|
| JC Medical Inc | 13.25% | -- |
| JenaValve Technology Inc | -10.34% | -- |
| Endotronix Inc | -10.34% | 1.65bn |
| Innovalve Bio Medical Ltd | -14.22% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DexCom Inc | 4.15bn | 535.20m | 33.51bn | 10.30k | 65.53 | 14.78 | 44.07 | 8.08 | 1.30 | 1.30 | 10.11 | 5.78 | 0.6269 | 2.89 | 3.89 | 402,718.40 | 8.09 | 8.79 | 12.44 | 11.75 | 60.72 | 64.97 | 12.90 | 14.90 | 1.32 | -- | 0.5246 | 0.00 | 11.34 | 22.27 | 6.41 | 41.63 | 14.79 | -- |
| GE HealthCare Technologies Inc | 19.80bn | 2.18bn | 35.03bn | 53.00k | 16.08 | 3.81 | 12.43 | 1.77 | 4.76 | 4.76 | 43.13 | 20.07 | 0.6018 | 5.54 | 4.51 | 373,547.20 | 6.84 | -- | 9.67 | -- | 41.99 | 40.35 | 11.37 | 10.78 | 0.7601 | 8.18 | 0.483 | 1.19 | 0.6138 | 3.41 | 43.48 | 3.82 | 3.91 | -- |
| Agilent Technologies Inc | 6.63bn | 1.17bn | 35.27bn | 18.00k | 30.56 | 5.75 | 24.44 | 5.32 | 4.06 | 4.06 | 23.09 | 21.61 | 0.576 | 3.08 | 5.07 | 370,279.30 | 10.13 | 10.93 | 12.25 | 13.09 | 53.77 | 53.35 | 17.59 | 17.93 | 1.60 | 24.95 | 0.3629 | 21.83 | -4.73 | 4.75 | 3.95 | 3.77 | 19.36 | 7.80 |
| Resmed Inc | 5.02bn | 1.31bn | 37.84bn | 9.98k | 28.98 | 6.82 | 24.88 | 7.54 | 8.91 | 8.91 | 34.05 | 37.83 | 0.6983 | 2.45 | 5.65 | 503,159.20 | 18.26 | 14.24 | 20.73 | 16.53 | 58.76 | 56.85 | 26.15 | 20.35 | 2.49 | 58.86 | 0.1082 | 32.62 | 10.95 | 12.44 | 13.75 | 19.98 | 8.23 | 5.89 |
| IDEXX Laboratories Inc | 3.93bn | 894.97m | 43.52bn | 11.00k | 50.00 | 30.17 | 42.29 | 11.07 | 10.82 | 10.82 | 47.53 | 17.93 | 1.20 | 3.87 | 6.81 | 357,439.60 | 27.26 | 28.11 | 40.01 | 42.15 | 61.28 | 59.56 | 22.76 | 22.19 | 0.8111 | 53.37 | 0.3937 | 0.00 | 6.46 | 10.12 | 5.07 | 15.73 | -3.35 | -- |
| Veeva Systems Inc | 2.86bn | 780.66m | 46.02bn | 7.29k | 59.75 | 7.39 | 56.03 | 16.12 | 4.71 | 4.71 | 17.25 | 38.11 | 0.4093 | -- | 6.06 | 391,622.10 | 11.19 | 11.33 | 13.85 | 14.35 | 75.50 | 72.60 | 27.34 | 23.96 | -- | -- | 0.00 | 0.00 | 16.20 | 19.99 | 35.84 | 18.85 | 36.56 | -- |
| Edwards Lifesciences Corp | 5.54bn | 1.44bn | 46.22bn | 15.80k | 32.51 | 4.56 | 29.29 | 8.35 | 2.42 | 7.00 | 9.31 | 17.28 | 0.4867 | 0.984 | 7.45 | 350,557.00 | 12.63 | 14.52 | 14.28 | 16.61 | 79.38 | 79.01 | 25.95 | 25.54 | 3.66 | -- | 0.0554 | 0.00 | 8.57 | 4.58 | 14.55 | 5.94 | 0.2857 | -- |
| Becton Dickinson and Co | 20.87bn | 1.50bn | 50.87bn | 74.00k | 34.37 | 2.02 | 13.16 | 2.44 | 5.16 | 5.16 | 71.96 | 88.07 | 0.3842 | 3.32 | 7.47 | 281,986.50 | 2.76 | 2.55 | 3.20 | 2.92 | 44.68 | 45.30 | 7.18 | 7.29 | 0.6427 | 7.18 | 0.4329 | 76.93 | 4.16 | 3.14 | 15.99 | 10.56 | -5.40 | 4.29 |
| Cencora Inc | 310.23bn | 1.69bn | 57.63bn | 42.00k | 34.51 | 56.89 | 20.49 | 0.1858 | 8.62 | 8.62 | 1,574.00 | 5.23 | 4.59 | 16.40 | 12.70 | 7,386,481.00 | 2.53 | 1.12 | 10.78 | 4.84 | 3.29 | 3.24 | 0.55 | 0.2556 | 0.517 | 17.30 | 0.8694 | 62.15 | 12.12 | 10.36 | -13.53 | 13.02 | 9.45 | 4.98 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 66.47m | 11.27% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 32.28m | 5.47% |
| Wellington Management Co. LLPas of 31 Mar 2025 | 27.53m | 4.67% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 25.78m | 4.37% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2025 | 16.03m | 2.72% |
| Citadel Advisors LLCas of 31 Mar 2025 | 13.19m | 2.24% |
| Geode Capital Management LLCas of 31 Mar 2025 | 12.68m | 2.15% |
| Walter Scott & Partners Ltd.as of 31 Mar 2025 | 11.39m | 1.93% |
| Fisher Asset Management LLCas of 31 Mar 2025 | 10.10m | 1.71% |
| Jennison Associates LLCas of 31 Mar 2025 | 10.09m | 1.71% |
